Bifidobacterium breve (B. breve)

Bifidobacterium breve is a Gram-positive, anaerobic, rod-shaped bacterium belonging to the genus Bifidobacterium within the phylum Actinobacteria. It is one of the first colonizers of the human infant gut microbiota—especially prevalent in breastfed infants—and can also be found in fermented dairy products such as cheese and yogurt. As a probiotic organism, it contributes to host health by fermenting carbohydrates into lactic and acetic acids, thereby acidifying its environment and inhibiting growth of potentially pathogenic bacteria. Clinical research has explored its use for prevention or adjunctive treatment in pediatric gastrointestinal diseases such as diarrhea, colic, celiac disease, obesity-related conditions, allergic disorders including rhinitis, and even neurodegenerative conditions like Alzheimer’s disease—though evidence varies by indication[2][3][4]. It does not function as a classical therapeutic target like an enzyme or receptor but rather acts through ecological modulation within the gut microbiome. Note: There is something incorrect about considering "Bifidobacterium breve" as a conventional therapeutic target such as an enzyme or receptor—it is instead a whole bacterial species used primarily for its probiotic effects rather than being directly targeted by drugs[2][3].

Bifidobacterium breve acts through competitive inhibition of pathogens in the gut microbiota and by producing lactic and acetic acids to lower intestinal pH.